֢ͪÇãÏòÌÇÄò²¡,ketosis-prone diabetes
1)ketosis-prone diabetes֢ͪÇãÏòÌÇÄò²¡
Ó¢ÎĶ̾ä/Àý¾ä

1.3-Feature Classification Scheme for Ketosis-Prone Diabetes and Predictive Value of Ketosis-Prone Diabetes Classification Schemes;֢ͪÇãÏòÌÇÄò²¡ÈýÖ¸±ê·ÖÐÍÔ¤²â¼ÛÖµÑо¿
2.Clinical Characteristics in Anti-islet Autoantibody-negative Ketosis-prone Patients with Metabolic Syndrome;¿¹ÌåÒõÐÔ֢ͪÇãÏòÌÇÄò²¡ºÏ²¢´úл×ÛºÏÕ÷»¼ÕßµÄÁÙ´²ÌØÕ÷̽ÌÖ
3.The Treatment of 176 Diabetic Ketosis and Diabetic Ketoacidosis PatientsÌÇÄò²¡ÍªÖ¢ºÍÌÇÄò²¡ÍªÖ¢ËáÖж¾176ÀýÖÎÁÆ·ÖÎö
4.Two alcoholic ketoacidosis cases misdiagnosed as diabetic ketoacidosis casesÒÒ´¼ÐÔ֢ͪËáÖж¾ÎóÕïÌÇÄò²¡ÍªÖ¢ËáÖж¾2Àý
5.The curative effect of insulin pump in treatment of diabetic ketoacidosis(DKA)ÒȵºËرÃÖÎÁÆÌÇÄò²¡ÍªÖ¢ËáÖж¾¹Û²ì
6.The 7 cases of gestational diabetes mellitus complicated with ketoacidosis.ÈÑÉïÆÚÌÇÄò²¡²¢ÍªÖ¢ËáÖж¾ÆßÀý±¨¸æ
7.Application of serum ¦Â-hydroxybutyric acid determination in diabetes and diabetes complicated with keto acidosisѪ¦Â-ôǶ¡ËáµÄ²â¶¨ÔÚÌÇÄò²¡¼°ÌÇÄò²¡ÍªÖ¢ËáÖж¾ÖеÄÓ¦ÓÃ
8.Patients with DKA also had a shorter symptom duration.ÓÐÌÇÄò²¡ÍªËáÖ¢µÄ²¡ÈËÆä·¢²¡Ç°Ö¢×´Ê±¼äÒ²½Ï¶Ì¡£
9.Effect of Pioglitazone on Inflammatory Markers in Type 2 Diabetes Mellitus;Æ¥¸ñÁÐͪ¶Ô2ÐÍÌÇÄò²¡Ñ×Ö¢±êÖ¾ÎïµÄÓ°ÏìÑо¿
10.Effect of Total Flavone of Pueraria Labata on Diabatic Neuropathy;¸ð¸ù×Ü»Æͪ¶ÔÌÇÄò²¡Éñ¾­²¢·¢Ö¢µÄÓ°Ïì
11.Tudy of Clinical Pathological Feature of 14 Cases with Hyperosmolar Non-Ketotic Diabetic Coma;14Àý¸ßÉøÐÔ·Ç֢ͪÌÇÄò²¡»èÃÔÁÙ´²·ÖÎö
12.The nursing care of a patient with type ¢ò diabetes mellitusl and ketoacidosis;1Àý¢òÐÍÌÇÄò²¡²¢ÍªÖ¢ËáÖж¾»¼ÕߵĻ¤Àí
13.Circulating FGF-21 Levels in the Patients with Type 2 Diabetes Mellitus and Diabetic Ketosis2ÐÍÌÇÄò²¡¼°Æä֢ͪ»¼ÕßѪ½¬FGF-21ˮƽ¸Ä±ä
14.Experiences on rescue and nursing care of coma patient due to diabetic ketoacidosisÌÇÄò²¡ÍªÖ¢ËáÖж¾»èÃÔ»¼ÕßµÄÇÀ¾È»¤ÀíÌå»á
15.Clinical Observation on Treatment of Diabetic Ketoacidosis(DKA) With Insulin PumpÒȵºËرÃÖÎÁÆÌÇÄò²¡ÍªÖ¢ËáÖж¾¼°»¤Àí
16.Practice to improve the quality of nursing records for patients with diabetic ketoacidosisÌÇÄò²¡ÍªÖ¢ËáÖж¾»¤Àí¼Ç¼Êéд·½·¨µÄ¸Ä½ø
17.Clinical application of insulin pump in treatment of aged diabetic ketoaciduriaÒȵºËرÃÔÚÀÏÄêÌÇÄò²¡ÍªÖ¢ÖÎÁÆÖеÄÁÙ´²Ó¦ÓÃ
18.Nursing Care for A Diabetic Patient with Lactic Acidosis and Ketoacidosis Induced by Drinking1ÀýÌÇÄò²¡ÈéËáÐÔ²¢ÍªÖ¢ËáÖж¾»¼ÕߵĻ¤Àí
Ïà¹Ø¶Ì¾ä/Àý¾ä

Diabetic ketosisÌÇÄò²¡ÍªÖ¢
1.Clinical observation on insulin pump in treatment of diabetic ketosis;ÒȵºËرÃÖÎÁÆÌÇÄò²¡ÍªÖ¢µÄÁÙ´²¹Û²ì
2.Objective:To study the precipitating factor¡¢treatment and Prevention of diabetic ketosis and diabetic ketoacidosis.Ä¿µÄ:Ñо¿ÌÇÄò²¡ÍªÖ¢¼°ÌÇÄò²¡ÍªÖ¢ËáÖж¾µÄÓÕÒò¡¢ÖÎÁƼ°Ô¤·À·½·¨¡£
3.Methods 40 Diabetic ketosis patients were randomized to receive either CSII by a portable insulin pump(n=20)or continuous intravenous insulin infusion(CVH)(n=20).Ä¿µÄ¹Û²ìÒȵºËرóÖÐøƤÏÂÊä×¢ÒȵºËØ(CSII)ÖÎÁÆÌÇÄò²¡ÍªÖ¢µÄÁÆЧ¡£
3)ketosis-prone֢ͪÇãÏò
1.Significance of islet auto-antibodies and ¦Â-cell function in patients with ketosis-prone diabetes;֢ͪÇãÏòµÄÌÇÄò²¡»¼ÕßÒȵº×ÔÉí¿¹ÌåÓëÒȵº¹¦ÄܵÄÒâÒå
2.Progress in ketosis-prone Type 2 diabetes mellitus֢ͪÇãÏòµÄ2ÐÍÌÇÄò²¡Ñо¿½øÕ¹
4)Diabetic ketoacidosisÌÇÄò²¡ÍªÖ¢ËáÖж¾
1.Clinical observation on insulin pump infusion in the treatment of diabetic ketoacidosis;ÒȵºËرÃÖÎÁÆ¢ñÐÍÌÇÄò²¡ÍªÖ¢ËáÖж¾ÁÙ´²¹Û²ì
2.An ultrastructure and cytohistochemical study of alveolar cells in rabbits with diabetic ketoacidosis;ÌÇÄò²¡ÍªÖ¢ËáÖж¾¼ÒÍ÷ÎÅݳ¬Î¢½á¹¹ºÍϸ°û»¯Ñ§µÄÑо¿
3.Effects of octreotide on manifest diabetic ketoacidosis;°ÂÇúëÄÔÚÌÇÄò²¡ÍªÖ¢ËáÖж¾ÖÎÁÆÖеÄÓ¦ÓÃÑо¿
5)diabetic ketoacidosis/DIÌÇÄò²¡ÍªÖ¢ËáÖж¾/Õï¶Ï
6)diabetic ketoacidosis/THÌÇÄò²¡ÍªÖ¢ËáÖж¾/ÖÎÁÆ
ÑÓÉìÔĶÁ

¸ßÉøÐÔ·Ç֢ͪÌÇÄò²¡»èÃÔ¸ßÉøÐÔ·Ç֢ͪÌÇÄò²¡»èÃÔ *ÌÇÄò²¡¼±ÐÔ´úлÎÉÂÒµÄÒ»¸öÁÙ´²ÀàÐÍ¡£ºÃ·¢ÓÚ50¡«70ËêÀÏÄ껼Õß¡£³£ÔÚ¸ÐȾ¡¢¼±ÐÔ賦Ñס¢ÒÈÏÙÑס¢ÄÔѪ¹ÜÒâÍâ¡£ÑÏÖØÉöÔ༲»¼¡¢ÑªÒºÍ¸ÎöÖÎÁÆÒÔ¼°Ä³Ð©Ò©ÎïÈçÌÇƤÖʼ¤ËØ¡¢ÃâÒßÒÖÖƼÁ¡¢àçàºÀàÀûÄò¼ÁµÈÓÕÒò×÷ÓÃÏ·¢Éú¡£±íÏÖΪÏÈÓжàÄò¡¢¶àÒû¡¢¶ñÐÄ¡¢Å»Í¡¢Ê§Ë®Öð½¥¼ÓÖØ£¬Ï¸°ûÄÚÍÑË®ÑÏÖØ£¬³öÏÖÉñ¾­¾«ÉñÖ¢×´£¬ÈçÊÈ˯¡¢»Ã¾õ¡¢¶¨ÏòÕÏ°­¡¢Æ«Ã¤¡¢ÉÏÖ«ÅÄ»÷Ñù´ÖÕð²ü¡¢ñ²ðïÑù³é´¤µÈ£¬×îºóÏÝÈë»èÃÔ£¬ÉõÖÁÐÝ¿Ë¡£ÊµÑéÊÒ¼ì²éΪ¸ßѪÌÇ£¬¸ßѪ½¬Éø͸ѹ£¬¶àÊý°éÓиßѪÄƺ͵ªÖÊѪ֢£¬ÑªÌǸßÖÁ33.3mmol£¯L(600mg£¯dl£©ÒÔÉÏ£¬ÑªÄÆ´ï150mmol£¯L»ò¸ü¸ß£¬±¾²¡²¡ËÀÂʽϸߣ¬¹ÊÓ¦ÔçÆÚÕï¶ÏºÍÖÎÁÆ¡£Ò»°ãÓÃС¼ÁÁ¿ÒȵºËؾ²ÂöµÎ×¢ÖÎÁÆ£¬Í¬Ê±Ó¦»ý¼«²¹Òº£¬×¢Òâ²¹³ä¼ØÑΣ¬²¢Òª×¢Òâ·ÀÖ¹ÄÔË®Ö׵ķ¢Éú£¬»ý¼«ÖÎÁÆÓÕ·¢ÒòËغͲ¢·¢Ö¢¡£